A Little Goes a Long Way – Why Even Small Amounts of Active Ingredients Can Prevent Protein Aggregation in Parkinson’s Disease

6. September 2024

Aggregation inhibitors are a promising approach to treating neurodegenerative diseases. Scientists at Heinrich Heine University Düsseldorf (HHU) and Forschungszentrum Jülich (FZJ) have now identified the mechanism by which the binding protein AS69 functions. In the journal Cell Reports Physical Science, they describe that an unexpectedly small amount of the substance is sufficient to prevent aggregation in the case of Parkinson’s disease.

Original paper

Celina M. Schulz, Emil D. Agerschou, Luis Gardon, Miriam Alexander, Matthias Stoldt, Henrike Heise, Gültekin Tamgüney, and Wolfgang Hoyer. Disordered regions of inhibitor-bound α synuclein suppress seed-induced fibril nucleation in cells. Cell Report Physical Science 102180 (2024). DOI: 10.1016/j.xcrp.2024.102180